Page last updated: 2024-12-10

ace-011

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ACE-011: a dimeric fusion protein consisting of the extracellular domain of the human ActRIIA linked to the Fc portion of human IgG1 and may be an effective therapy in a variety of diseases involving bone loss [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	2877953
SCHEMBL ID	2204761
MeSH ID	M0537365

Synonyms (24)

Synonym
CBMICRO_030367
ace-011
OPREA1_342150
DIVK1C_005743
CDS1_004703 ,
BIM-0030123.P001
n-(2-ethoxy-4-nitrophenyl)acetamide
AKOS001044796
116496-76-5
4-acetamido-3-ethoxynitrobenzene
acetamide, n-(2-ethoxy-4-nitrophenyl)-
PS-6223
AB07920
acetamide,n-(2-ethoxy-4-nitrophenyl)-
n-(2-ethoxy-4-nitrophenyl) acetamide
XZWVZJDHIDYKPB-UHFFFAOYSA-N
mfcd00994990
SCHEMBL2204761
DTXSID60387001
SR-01000223946-1
sr-01000223946
FT-0715219
4-(4-ethoxycarbonylthiazol-2-yl)piperazine-1-carboxylic acid tert-butyl ester
Z56871699

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Sotatercept was generally safe and well tolerated, and elicited clinically significant, dose-dependent increases in hemoglobin, hematocrit, and red blood cell counts that persisted for up to 4 months."	( Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. Borgstein, NG; Chen, N; Kim, K; Kumar, R; Laadem, A; Mook, L; Sherman, ML; Wilson, D; Yang, Y, 2013)	0.39

Pharmacokinetics

Excerpt	Reference	Relevance
" Here, we evaluated the safety, pharmacokinetic properties, and pharmacodynamic effects of sotatercept in 31 healthy postmenopausal women."	( Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. Borgstein, NG; Chen, N; Kim, K; Kumar, R; Laadem, A; Mook, L; Sherman, ML; Wilson, D; Yang, Y, 2013)	0.39

Dosage Studied

Excerpt	Relevance	Reference
" The absorption after subcutaneous dosing was essentially complete."	( Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. Condon, CH; Jacobs, M; Kramer, W; Kumar, R; Pearsall, AE; Ruckle, J; Seehra, J; Sherman, ML; Underwood, KW; Yang, Y, 2009)	0.59
" A particular emphasis is given to the relationship between sotatercept dosage and its efficacy or associated adverse reactions."	( From bench to bedside: The promise of sotatercept in hematologic disorders. Lan, Z; Lv, Z; Xiao, Y; Zuo, W, 2023)	0.91

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (2.17)	29.6817
2010's	29 (63.04)	24.3611
2020's	16 (34.78)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	24.98 (24.57)
Research Supply Index	4.06 (2.92)
Research Growth Index	5.70 (4.65)
Search Engine Demand Index	26.67 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (24.98)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (21.28%)	5.53%
Reviews	10 (21.28%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (57.45%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
hydroxyurea [no description available]	2.1	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
activins Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.	7.07	9	0
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.19	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	3.19	1	0	diazine; pyrazines	Daphnia magna metabolite
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	9.43	1	1	elemental platinum; nickel group element atom; platinum group metal atom
bortezomib [no description available]	3.19	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.19	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
everolimus [no description available]	3.19	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
carfilzomib [no description available]	3.19	1	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.51	2	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	4.91	1	1
incb-018424 [no description available]	3.25	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	4.62	1	1	polypeptide
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	9.98	9	3

Condition	Relationship Strength	Studies	Trials
Heritable Pulmonary Arterial Hypertension [description not available]	5.95	5	1
Anoxemia [description not available]	2.41	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.29	6	0
Pulmonary Hypertension [description not available]	7.35	5	2
Innate Inflammatory Response [description not available]	2.41	1	0
Pulmonary Arterial Hypertension A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.	8.77	18	3
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.41	1	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	7.35	5	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.41	1	0
Familial Primary Pulmonary Hypertension Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.	5.95	5	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	16.95	15	9
Disease Exacerbation [description not available]	3.51	2	0
Cryptogenic Fibrosing Alveolitis [description not available]	3.52	1	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	3.52	1	0
Anemia With Multinucleated Erythroblasts [description not available]	2.25	1	0
Thrombopenia [description not available]	4.62	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	4.62	1	1
Chronic Kidney Diseases [description not available]	3.95	2	0
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	3.95	2	0
Thalassemias [description not available]	3.06	1	0
Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.	3.06	1	0
Dysmyelopoietic Syndromes [description not available]	8.84	6	4
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	8.84	6	4
Anemia, Cooley's [description not available]	9.17	9	4
beta-Thalassemia A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.	9.17	9	4
Anemia, Congenital Hypoplastic, Of Blackfan And Diamond [description not available]	3.46	2	0
Anemia, Diamond-Blackfan A rare congenital hypoplastic anemia that usually presents early in infancy. The disease is characterized by a moderate to severe macrocytic anemia, occasional neutropenia or thrombocytosis, a normocellular bone marrow with erythroid hypoplasia, and an increased risk of developing leukemia. (Curr Opin Hematol 2000 Mar;7(2):85-94)	3.46	2	0
Kahler Disease [description not available]	5.72	2	1
Bone Diseases Diseases of BONES.	3.01	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	5.72	2	1
Hemoglobinopathies A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.	3.01	1	0
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	4.4	1	1
Hypercoagulability [description not available]	2.1	1	0
A-Thalassemia [description not available]	2.1	1	0
Hemoglobinuria The presence of free HEMOGLOBIN in the URINE, indicating hemolysis of ERYTHROCYTES within the vascular system. After saturating the hemoglobin-binding proteins (HAPTOGLOBINS), free hemoglobin begins to appear in the urine.	2.1	1	0
alpha-Thalassemia A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted.	2.1	1	0
Iron Overload An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)	3.43	2	0
Thrombophilia A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.	2.1	1	0
Bone Cancer [description not available]	3.01	1	0
Breast Cancer [description not available]	10.73	2	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.01	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	5.73	2	1
Bone Loss, Osteoclastic [description not available]	7.47	4	4
Low Bone Density [description not available]	2.05	1	0
Bone Diseases, Metabolic Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.	2.05	1	0

chemdatabank.com